Articles tagged with Drug Studies
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
The Liberty Asthma VOYAGE trial found that dupilumab significantly reduced the rate of severe exacerbations by nearly 60% and improved lung function and asthma control in children ages 6 to 11. Dupilumab was also shown to be safe, with minimal adverse reactions.
A new Australian study has found that taking anxiety drugs like nitrazepam and antidepressants before hip or knee surgery can lead to postoperative delirium. The risk is particularly high for older patients, highlighting the need to adjust medication regimens before undergoing elective procedures.
A study found that US clinical trials of new drugs and biologics lack adequate representation of racial and ethnic populations. The research highlights the need for greater diversity in clinical trial participation to ensure the safety and efficacy of treatments for all patients.
The study used multigene sequencing to identify genomic alterations in patients with metastatic breast cancer. Patients with genomic alterations ranked as ESCAT I/II saw improved progression-free survival with targeted therapies matched to their genomic changes, while those without these alterations did not benefit from the treatment.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
A new meta-analysis published in the European Journal of Preventive Cardiology suggests that Sodium-glucose co-transporter-2 (SGLT2) inhibitors can improve outcomes for heart failure patients with preserved ejection fraction. The medication has been shown to reduce the risk of death from heart-related causes and hospitalization by 22%.
A new study published in the Journal of Experimental Medicine showed that a fast-tracked stroke drug, 3K3A-APC, protected mice from injury to the brain's white matter, a leading cause of dementia. The drug may also be effective in slowing down progression of cognitive impairment.
A phase 3 clinical trial found that teriflunomide reduced new or enlarged lesions in children with multiple sclerosis, suggesting potential benefits. However, the medication did not delay time to the next clinical relapse.
A study published in the American Journal of Respiratory and Critical Care Medicine found that prostacyclin treatment reduced damage to vital organs and halved mortality rates among critically ill Covid-19 patients. The research team hopes to investigate larger patient populations in future studies.
Researchers at the University of Ottawa have made a breakthrough in reversing memory deficits and slowing disease progression in female mouse models of Alzheimer's disease. The study found that activating a specific receptor was effective in treating females, who make up two-thirds of diagnosed cases.
A Michigan Medicine study found that only 7.4% of patients received naloxone and 8.5% received buprenorphine prescriptions within 30 days of an opioid overdose. The low rates highlight missed opportunities for equipping patients with rescue medicines to use in case of future overdoses.
Researchers developed a predictive model that maps electric activity of mouse, rabbit, and human cardiac cells, allowing translation of findings across species. The model is expected to accelerate drug development and improve understanding of disease mechanisms.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
A Henry Ford Health System study published in The American Journal of Sports Medicine found that a novel opioid-free pain management protocol provided the same pain relief for patients as common types of prescription opioids. This approach aims to reduce opioid misuse and promote more effective pain management after ACL knee reconstruc...
A nationwide study found that hospitalized COVID-19 patients taking immunosuppressive medications did not have a significantly increased risk of dying from COVID-19 or being put on a ventilator compared to non-immunosuppressed patients. However, patients taking rituximab were at a substantially increased risk of death.
A recent study published in Circulation found that patients receiving a combination of antiplatelet drugs for many months (up to 2.5 years) after stent procedures may not receive the full benefit of treatment. The researchers compared characteristics of 8,864 patients from an older trial to 568,540 contemporary patients and determined ...
A phase 2 clinical trial found that losartan, commonly used to treat high blood pressure, did not significantly slow down the progression of Alzheimer's disease in people with mild-to-moderate symptoms. However, the drug may still be beneficial for those with early-stage disease if prescribed for longer periods.
A study with lab-grown mouse cells reveals that lamin C plays a key role in maintaining the structural network under the cell's nucleus, ensuring proper DNA organization. This finding has significant implications for diagnosing and treating genetic disorders linked to DNA disorganization, such as progeria and muscular dystrophy.
A multi-center study assesses medicinal mushrooms and Chinese herbs for therapeutic benefit in treating acute COVID-19 infection. The MACH-19 trial evaluates the safety and feasibility of two investigational compounds, one in capsule form and another as a Chinese herbal formula.
A new anti-diabetic compound, Montbretin A (MbA), has been approved by Health Canada for Phase 1 human trials. MbA works by inhibiting the alpha-amylase enzyme, slowing down starch breakdown and reducing blood sugar spikes in Type 2 diabetics.
Researchers are modifying an arm of a worldwide clinical trial to evaluate a combination of drugs targeting two brain proteins: amyloid and tau. The Tau NexGen Trial aims to test the effectiveness of these treatments in slowing disease progression by targeting both Alzheimer's disease pathologies.
A study published in Translational Psychiatry found that patients with high expectations of SSRI treatment showed a four times higher improvement rate compared to those with low expectations. The effect was attributed to the influence of dopamine on the brain's reward pathways.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
Scientists from Japan discover IL-36Ra plays a pivotal role in wound healing, and Cl-amidine normalizes exacerbated I/R injury. The study's findings suggest IL-36Ra as a potential therapeutic target for cutaneous I/R injuries.
Researchers have discovered that a low-dose oral compound, HBI-002, can safely reduce oxidative stress and inflammation in the retina, common causes of diabetic retinopathy. The study suggests that small amounts of carbon monoxide may help protect vision in diabetes patients.
Researchers at Mount Sinai have developed a diverse library of well-characterized human induced pluripotent stem cell lines from clinically healthy individuals, offering valuable resources for studying normal human biology, evaluating drug responses, and disease modeling.
Trials that met their primary endpoint were more commonly published in journals with higher impact factors, suggesting a correlation between trial outcome and publication quality. Additionally, publications of trials leading to FDA approvals and those in high-impact journals were associated with increased Research Citation Rates.
A recent survey of advanced breast cancer patients in the UK reveals that only 14% have been recruited to a trial, highlighting a need for improved access. Patients often face barriers, including clinician reluctance to discuss trials and a lack of patient-friendly databases.
A new analysis finds that 67 million US adults identify as disabled, with significant disparities among different socioeconomic and demographic groups. The study highlights the need for accurate data on disability to inform effective policies and solutions.
Researchers at Johns Hopkins Medicine found that antibody levels against SARS-CoV-2 stay higher in people who were infected by the virus and then received protection from mRNA vaccine compared to those who only got vaccinated. A longer interval between virus exposure and first vaccine dose may enhance antibody response.
Itepekimab, a novel monoclonal antibody, has been found to be safe and effective in treating moderate-to-severe asthma. In a phase 2 trial, it significantly improved lung function and reduced asthma control events compared to placebo.
A five-year study aims to identify hormone responses in a population of Mexican Americans with prediabetes, Type 2 diabetes, and obesity. The research uses genetic data and physiologic testing to guide optimal treatments for diabetes, prediabetes, and related diseases.
A study co-led by McMaster University found that fluvoxamine can save the lives of COVID-19 patients and reduce hospital admissions by up to 30%. The treatment was effective in preventing COVID-19 from becoming a life-threatening illness when administered early.
Researchers at Shanghai Institute of Materia Medica have isolated and characterized seven novel dimeric sesquiterpenoids with potent antimalarial activities. The most potent compound, Shizukaol A, exhibits an EC50 value 1000-fold more active than artemisinin.
The largest trial to date shows that fluvoxamine treatment for high-risk outpatients with early-diagnosed COVID-19 reduces the need for prolonged observation or hospitalization. The study found an absolute reduction in risk of prolonged hospitalization and a relative risk reduction of 32% compared to the control group.
A recent Johns Hopkins Medicine-led study suggests that statin use is not beneficial for reducing COVID-19 mortality or severity. Instead, patients taking statins had an increased risk of developing a more severe form of the disease. The researchers found no significant impact on mortality rates.
A Singapore clinical trial has introduced a new way to treat advanced hepatocellular carcinoma by combining nivolumab, an immunotherapy drug, with yttrium-90 resin microspheres radioembolisation. The study shows promising results in treating intermediate and advanced HCC, with an overall response rate of 30.6%.
Researchers have discovered a more effective treatment for children with Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C), a rare COVID-19 reaction. The new therapy, infliximab, reduces fever duration, hospitalizations, and anemia compared to standard IVIG treatment.
A study by University of Toronto researchers found that using prescription stimulant medications increased the risk of cardiovascular events by 40% in older adults within the first 30 days. The risk was highest during initial use, but decreased over time as patients stopped taking the medication.
A new study reveals that rural Americans face significant challenges in accessing COVID-19 treatment trials, with many living more than an hour away from the nearest trial site. Native Americans and Alaska Natives are particularly affected, with over 50% living more than 60 minutes from a trial site.
Research reviews show that back pain in space is often sciatica, a form of back pain radiating down the legs. Astronauts experience changes in spine curvature due to microgravity, leading to acute and chronic pain upon return to Earth.
A new study has shown that a commonly prescribed antidepressant for agitation in people with dementia is no more effective than a placebo and may even increase mortality. The research found no improvement in agitation symptoms among those taking mirtazapine, a drug previously thought to be beneficial.
Researchers found that adding interferon to bone marrow transplant significantly reduced leukemia relapse among high-risk patients, improving outcomes. The study suggests a potential new strategy for treating advanced acute myeloid leukemia, with further research needed to confirm the findings.
About 42% of U.S. adults are considered clinically obese due to increased risk of health conditions such as diabetes and heart disease. New weight-loss drugs like Wegovy (semaglutide) show promise in safely aiding weight loss, but long-term side effects and sustainability remain concerns.
Researchers at University of Pittsburgh and Prairie View A&M University developed an algorithm to repurpose cancer drugs for pulmonary hypertension, a devastating lung disease. Two compounds improved human cells and rodent markers, supporting broader drug-repurposing platform use.
A meta-analysis of randomized controlled trials found lactoferrin to have promising efficacy in reducing the risk of respiratory tract infections, including COVID-19. Lactoferrin may also play a beneficial role in managing symptoms and recovery for patients suffering from RTIs.
Researchers have identified several commonly prescribed medications that can affect the flu virus's interaction with host cells. Some of these medications amplify the virus's effect, while others dampen it, depending on their target in the cells. Further research is needed to understand the consequences of these interactions for patients.
Researchers discovered a mechanism that could prove useful in treating heart failure with preserved ejection fraction (HFpEF), a common and hard-to-treat condition. The new approach reduces exposure to increased cardiac stiffness, which is associated with lower-filling pressures inside the heart chambers.
Two new studies examine rising cancer drug spending in the US, finding that many patients receive treatments with no documented overall survival benefit. The studies suggest that the combination of regulatory, pricing, and reimbursement policies contributes to wasteful healthcare spending.
A phase II clinical trial has shown that the DNA alkylation drug DM-CHOC-PEN improved survival in adolescent and young adult patients with central nervous system cancers. The treatment was well-tolerated, with no severe toxicities observed, and showed potential for combination with other treatments.
Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.
Researchers found a chemical inhibitor of PDE9 stimulates cells to burn more fat in mice, reducing obesity and fatty liver. The study's findings suggest the experimental drug may be effective in treating severe obesity and improving heart function.
A new study suggests that increased access to naloxone has not changed people's perception of the risks associated with heroin use. Researchers found that individuals who used heroin and those living in areas with easy or restricted access to naloxone both perceived heroin as a high-risk substance.
A simulated screening process for a pancreatic cancer clinical trial showed that Black patients were significantly more likely than white patients to be excluded from trials. The study found that nutrition and infectious disease criteria disproportionately excluded Black patients, while a history of prior cancer treatment excluded more...
The ARAMIS phase III clinical trial found that darolutamide improved metastasis-free survival and overall survival in Black/African American patients. Darolutamide-treated patients had a higher three-year overall survival rate and longer time to disease progression compared to placebo-treated patients.
A pre-clinical study by University of Illinois Chicago researchers shows that a drug targeting specific immune pathways can prevent lung damage and death in mice infected with the SARS-CoV-2 virus. The study suggests targeted treatments may be more suitable for COVID-19 patients than broad immune suppressants.
A study analyzing 60 US emergency departments found medication harms were a common cause of visits in 2017-2019, with variation in products and patient age. The data highlighted the need for improved safety measures and monitoring systems to mitigate such incidents.
A team of scientists developed a new method to study the effects of reactive electrophiles in the body. By targeting specific proteins with electrophilic compounds, they discovered novel mediators involved in immune-cell apoptosis triggered by Tecfidera, a multiple sclerosis treatment.